|
Post by otherottawaguy on Sept 12, 2016 6:59:48 GMT -5
|
|
|
Post by otherottawaguy on Sept 1, 2016 15:21:27 GMT -5
What is 10% of .735?
What is tomorrow's low end close: .7352 - .0735 = .6617 if they follow today's game plan and no numbers are reported.
From what I have noticed though they tend to get nervous about weekends so I would be surprise if it closes there but Monday, all bets are off.
As to your call of $0.65 I would agree that we might see that intraday tomorrow.
I am looking for this to bottom around the mid 60's and then the numbers will begin to improve into end Sept due to increasing script numbers.
OOG
|
|
|
Post by otherottawaguy on Sept 1, 2016 14:10:57 GMT -5
Yesterday may also have been a result of AF's tweet which lead to the Bull rush.
Really interested to see where this parks at day end.
|
|
|
Post by otherottawaguy on Sept 1, 2016 13:34:45 GMT -5
Anyone noticing that they are not taking this below .721. Afraid to hit the 10% decline line.
How long does short selling get suspended for when a stock closes down 10%>
Might see it dip below in the last hours, but my gut says it closes no lower.
OOG
|
|
|
Post by otherottawaguy on Aug 30, 2016 8:56:51 GMT -5
Same User Id that is used here and has been confirmed as him.
OOG
|
|
|
Post by otherottawaguy on Aug 29, 2016 13:51:43 GMT -5
The links above seem to be working.
FDA site says that a transcript will be avail 30 days following the conference.
|
|
|
Post by otherottawaguy on Aug 26, 2016 14:11:30 GMT -5
Seems to be a conference in Calgary, Alberta, Canada.
Couldn't help the shameless plugging...
OOG
|
|
|
Post by otherottawaguy on Aug 16, 2016 19:40:37 GMT -5
We now just need the other 2000+ members of this board to step up and each buy another 25000 ...
|
|
|
Post by otherottawaguy on Aug 15, 2016 14:32:36 GMT -5
Saw this back before the last conference. Glad to see they were there.
"American Association of Diabetes Educators." (I think)
|
|
|
Post by otherottawaguy on Aug 4, 2016 15:49:20 GMT -5
From the other board just in case the links are not working:
School of medicine - University of Colorado
The purpose of this study is to evaluate the blood levels of the study medication (Afrezza®), for blood sugar levels and safety after 4 weeks of treatment in children and adolescents between 4-17 years of age with T1DM
Age 4-17 years Type 1 Diabetes for at least 1 year A1C between 7-10% Stable Insulin doses for the past 6 weeks
8/2/2016 Immune System Diseases
|
|
|
Post by otherottawaguy on Jul 12, 2016 16:38:58 GMT -5
Good Summary on yahoo from surplus.value:
surplus.value • 1 hour 4 minutes ago
9users liked this postsusers disliked this posts0Reply
MNKD presentation today at Cantor
Mike presented (dont know what happened to Matt?) -Funds until Q1 2017 -10 million /month burn rate -7-8 out of 10 patients are being approved by insurance .. very positive -Coverage by Aetna and Express already , CVS and UNITED coming along, Medicare slower and will be about 1.5 years before medicare is fully present (process takes much longer) - are targeting 3/4 of diabetes market -protocols for pediatric should be ready before end of 2016 may facilitate use in externals markets as an inroad. - use two of the studies presented at ADA to push for a label change -July 25 or earlier MNKD's own product will be distributing (and 100% goes to MNKD) Some issue with Sanofi's supply which has 6 month expiry (DEC) so some issue with pharmacies stocking it. Will speak to Sanofi and also MNKDs own supply will be now used. -Spirometry not a problem , being taken care of . -- MNKD own patient reimbursement program launching Aug 1 and is well organized (online) "MNKD cares" -Late August sample packs for new adopters and will have sufficient supply dosages to offset any problems with lasting for early patients - 180 count titration packs to also deal with new patients running out 60's of 4, 8, 12 (180 total) and 90 count packs of 8 and 12 -Price renegotiation revisited as demand and sales increase. -Not looking for partner in US -working on foreign deal but good deal difficult until US sales ramp up. - should see script numbers bottom out in july and start to increase in next few months August and onwards -Controlling costs - still pursuing Technosphere applications ( 3 main ones already discussed previously ) which are not costing much now and seeking partners for these - End of year milestone payment coming but cant discuss due to NDA Thats all I managed to write down. Mike knows what hes doing. Very confident. Finally MNKD has someone on the ball.
|
|
|
Upgrades
Jul 7, 2016 6:38:57 GMT -5
via mobile
Post by otherottawaguy on Jul 7, 2016 6:38:57 GMT -5
Sports: Hate to tell you this but Griffin Securities dropped coverage about two weeks ago.
OOG
|
|
|
Post by otherottawaguy on Jun 23, 2016 7:04:38 GMT -5
|
|
|
Post by otherottawaguy on Jun 23, 2016 7:00:24 GMT -5
Thought I would start a new thread to capture references to TA of MNKD
|
|
|
Post by otherottawaguy on Jun 21, 2016 8:21:15 GMT -5
At least Dr Markey gives them a nice send off...
GRIFFIN SECURITIES Member FINRA, SIPC
Keith A. Markey, Ph.D., M.B.A. Stock Symbol NASDAQ: MNKD Current Price $1.00 12 mos. Target Price NA Market Cap $477.7 mln MannKind Corp. SUSPENDING COVERAGE Suspending Coverage : Pharmaceuticals
Terminating Coverage of MNKD Shares We are suspending coverage of MannKind Corporation with this report as part of a reallocation of our resources. Our past reports and earnings estimates should not be used for investment decisions.
The Company is undertaking several initiatives to market Afrezza®. The plan, which was outlined over the past few months, is designed to address several key areas that contributed to the weak sales registered during the Sanofi collaboration that ended April 5th: Physician detailing will be highly targeted to the 5,000 - 7,000 doctors who write prescriptions accounting for about 66% of the insulin market. MannKind is hiring 55 experienced reps (out of a pool of 3,000 applicants) to help doctors, notably endocrinologists, titrate the dosage to optimize the therapy and teach their patients how to use the inhalable insulin. The detailing effort, which will commence in July, will follow several presentations made at the American Diabetes Association meeting earlier this month that underscored the unique properties of Afrezza versus injectable insulin. Efforts will soon be under way to improve patient acceptance. The Company will help patients find local doctors trained in the use of Afrezza and it is working to improve insurance coverage. These steps will complement improved packaging that will provide a variety of dosages in a titration box to facilitate dose optimization and promote broad patient acceptance. Also, the lung function test that is required prior to initiating treatment should be available in most physicians’ offices soon via a simple, handheld spirometer. The Afrezza brand name should become better known, partly through direct-to-consumer advertising in targeted markets as well as through social media. We believe the campaign will be initiated in September quarter, since the drug will be available for the first time under the MannKind name starting in July.
The Company plans to maintain tight control over expenses. The monthly cash utilization rate should remain in the range of $10 - $12 million, despite the incremental selling costs. This means there is sufficient cash on hand following an equity financing in May to support operations into next year. A marketing partnership, which we believe is likely with evidence of growing sales in the United States, would likely provide non-dilutive financing and further acceptance of Afrezza.
|
|